JP2024501581A5 - - Google Patents

Info

Publication number
JP2024501581A5
JP2024501581A5 JP2023558307A JP2023558307A JP2024501581A5 JP 2024501581 A5 JP2024501581 A5 JP 2024501581A5 JP 2023558307 A JP2023558307 A JP 2023558307A JP 2023558307 A JP2023558307 A JP 2023558307A JP 2024501581 A5 JP2024501581 A5 JP 2024501581A5
Authority
JP
Japan
Prior art keywords
seq
cdr
antibody
sequence containing
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023558307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501581A (ja
JP7825633B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062099 external-priority patent/WO2022125482A1/en
Publication of JP2024501581A publication Critical patent/JP2024501581A/ja
Publication of JP2024501581A5 publication Critical patent/JP2024501581A5/ja
Application granted granted Critical
Publication of JP7825633B2 publication Critical patent/JP7825633B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023558307A 2020-12-08 2021-12-07 ガレクチン－３に対する抗体及びその使用方法 Active JP7825633B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063122714P 2020-12-08 2020-12-08
US63/122,714 2020-12-08
PCT/US2021/062099 WO2022125482A1 (en) 2020-12-08 2021-12-07 Antibodies to galectin-3 and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024501581A JP2024501581A (ja) 2024-01-12
JP2024501581A5 true JP2024501581A5 (OSRAM) 2024-12-16
JP7825633B2 JP7825633B2 (ja) 2026-03-06

Family

ID=81973696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558307A Active JP7825633B2 (ja) 2020-12-08 2021-12-07 ガレクチン－３に対する抗体及びその使用方法

Country Status (4)

Country Link
US (1) US20240026009A1 (OSRAM)
EP (1) EP4259201A4 (OSRAM)
JP (1) JP7825633B2 (OSRAM)
WO (1) WO2022125482A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
CN118978593B (zh) * 2023-11-07 2025-07-15 深圳市睿盟创新生物科技有限公司 人半乳糖凝集素-3蛋白水平的测定方法及应用
CN121263444A (zh) * 2024-03-08 2026-01-02 孙氏医药有限公司 抗半乳糖凝集素3抗体和其在癫痫和相关疾病中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902841A1 (en) * 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
HUE051246T2 (hu) * 2015-05-30 2021-03-01 Molecular Templates Inc Deimmunizált shigatoxin alegység vázak és azokat tartalmazó, sejthez irányító molekulák
JP6925981B2 (ja) * 2016-01-06 2021-08-25 株式会社オーダーメードメディカルリサーチ Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
EP3658172A4 (en) * 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
EP3466975A1 (en) * 2017-10-05 2019-04-10 Laboratoire Français du Fractionnement et des Biotechnologies A specific binding molecule directed against galectin-3 protein
EP3746123A4 (en) * 2018-02-01 2021-12-01 Memorial Sloan-Kettering Cancer Center ANTIBODIES DIRECTED AGAINST GALECTIN-3 AND THEIR METHODS OF USE
CN113711036B (zh) * 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途

Similar Documents

Publication Publication Date Title
Paul et al. Cancer therapy with antibodies
JP2021512604A5 (OSRAM)
CN115052893A (zh) 抗tigit抗体和使用方法
Presta Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
RU2335507C2 (ru) Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
US20160009824A1 (en) Tetravalent bispecific antibodies
JP2023516004A5 (OSRAM)
JP2019536470A5 (OSRAM)
CN115052896A (zh) 抗ror1抗体和组合物
JP2023543031A5 (OSRAM)
WO2022121980A1 (zh) 抗SIRPα抗体及其用途
EP3237006A1 (en) Bispecific tetravalent antibodies and methods of making and using thereof
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
CN113150156B (zh) 抗tigit抗体及其用途
JP2023529842A5 (OSRAM)
JP2022553922A5 (OSRAM)
JP2024016024A5 (OSRAM)
JP2022513050A5 (OSRAM)
JP2023536461A5 (OSRAM)
JP2020502233A5 (OSRAM)
JP2024001073A5 (OSRAM)
JP2023516941A5 (OSRAM)
JP2024515560A5 (OSRAM)
WO2023186063A1 (zh) 抗pvrig抗体、其药物组合物及用途
JP2024543822A5 (OSRAM)